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https://doi.org/10.1016/j.celrep.2020.108159SUMMARYHelicobacter pylori (Hp) is an important human pathogen associatedwith gastric inflammation and neoplasia.
It is commonly believed that this bacterium avoids major immune recognition by Toll-like receptors (TLRs)
because of low intrinsic activity of its flagellin and lipopolysaccharides (LPS). In particular, TLR5 specifically
detects flagellins in various bacterial pathogens, while Hp evolved mutations in flagellin to evade detection
through TLR5. CancerogenicHp strains encode a type IV secretion system (T4SS). The T4SS core component
and pilus-associated protein CagY, a large VirB10 ortholog, drives effector molecule translocation. Here, we
identify CagY as a flagellin-independent TLR5 agonist. We detect five TLR5 interaction sites, promoting bind-
ing of CagY-positive Hp to TLR5-expressing cells, TLR5 stimulation, and intracellular signal transduction.
Consequently, CagY constitutes a remarkable VirB10 member detected by TLR5, driving crucial innate im-
mune responses by this human pathogen.INTRODUCTION
Helicobacter pylori (Hp) is a paradigm of chronic infections and
major risk factor for the development of severe gastric diseases,
including malignancies (Peek and Blaser, 2002; Fox and Wang,
2007). Gastric cancer represents the fifth frequently detected
cancer type worldwide with up to 952,000 new cases reported
annually (Ferlay et al., 2015). A crucial bacterial determinant
associated with gastric disease is the cag pathogenicity island
(cagPAI), encoding a type IV secretion system (T4SS). This
T4SS includes32 genes covering all VirB1 to VirB11 orthologs,
VirD4, and various unique components. Reported translocated
effector molecules involve peptidoglycan (Viala et al., 2004),
genomic DNA (Varga et al., 2016), ADP-heptose (Pfannkuch
et al., 2019), and the immunodominant protein CagA, which is
phosphorylated by host tyrosine kinases (Grohmann et al.,
2018). Recent studies identified a T4SS core complex
comprising five proteins: Cag3, CagM, CagT, CagX, and CagY
(Frick-Cheng et al., 2016; Chung et al., 2019). T4SS-pili forma-
tion is induced upon host cell contact by infected bacteria
(Rohde et al., 2003; Kwok et al., 2007). Two proteins are known
to be exposed at the pilus surface: CagY (Rohde et al., 2003) and
CagL (Kwok et al., 2007). Both proteins were also reported toCe
This is an open access article under the CC BY-Ndirectly interact with the host receptor integrin-a5b1; CagL uses
multiple binding sites (Kwok et al., 2007; Barden et al., 2013; Bö-
nig et al., 2016), while CagY interacts via the C-terminal domain
(Jiménez-Soto et al., 2009). CagY is related to VirB10 of the
T4SSs in other bacteria; however, CagY exhibits an additional
large N-terminal domain (Grohmann et al., 2018). This domain
comprises two large repeat sections, revealing an extraordinary
structural variability in CagY both by in-frame deletion and dupli-
cation events (Liu et al., 1999; Aras et al., 2003; Delahay et al.,
2008; Barrozo et al., 2013; Beckett et al., 2018; Sierra et al.,
2019). Interestingly, the rearrangements in CagY are immune-
driven by the host, sufficient to trigger gain or loss of T4SS func-
tion (Barrozo et al., 2013). Thus, it has been proposed that the
CagY repeats may operate as a molecular ‘‘switch’’ or a ‘‘rheo-
stat’’ to fine tune host inflammatory responses in order to ensure
chronicHp infection. However, the exact function of the repeats,
and whether they are used in direct host cell interactions, is yet
unknown.
Toll-like receptors (TLRs) constitute a crucial family of path-
ogen recognition receptors (PRRs) that sense evolutionarily
conserved structures in microbes (Iwasaki and Medzhitov,
2004; Beutler, 2009). A prototypic member of this class of innate




OPEN ACCESSexclusively sense bacterial flagellins (Yoon et al., 2012; Ander-
sen-Nissen et al., 2005; Song et al., 2017). TLR5 recognizes
the conserved D1 domain in flagellins expressed by Salmonella,
Vibrio, and other human pathogens. The D1 domain appears to
be essential both for the assembly of the flagellar apparatus
and for motility of the bacteria. In addition, the D0 domain of fla-
gellins is also involved in TLR5 activation, suggesting that TLR5
can specifically sense two distinguished motifs in flagellins (For-
stneric et al., 2017). In contrast, the flagellins of some other path-
ogens such asCampylobacter,Bartonella, andHp are not recog-
nized by TLR5 but are required for bacterial motility to effectively
infect their hosts (Andersen-Nissen et al., 2005). The sites
responsible for TLR5 evasion were mapped to amino-acid resi-
dues 89–96 in the D1 domain. While Salmonella flagellin (FliC)
is strongly recognized by TLR5, mutation of residues 89–96 by
the corresponding FlaA sequence in Hp terminates TLR5 recog-
nition and also abrogates motility. In order to maintain bacterial
motility, various a- and ε-proteobacteria acquired compensatory
amino-acid substitutions elsewhere in the flagellin. These data
led to the hypothesis that TLR5 evasion is essential for a sub-
group of bacteria such as Hp to survive at mucosal surfaces in
mammals and that flagellin receptors shaped the evolution of
the flagellin molecules (Andersen-Nissen et al., 2005).
However, we have previously shown that Hp infection acti-
vated TLR5 in a flagellin-independent fashion (Pachathundi-
kandi et al., 2011). Remarkably, tlr5/ mice were unable to
control Hp infections compared to wild-type (WT) mice, accom-
panied by vigorously diminished Th1 responses and pathology
in the gastric mucosa (Pachathundikandi et al., 2019). Interest-
ingly, chronic colonization of WT mice with T4SS-defective
mutant Hp phenocopied the outcomes of TLR5 absence with
regard to gastric Th1 responses. Thus, unlike the findings dis-
cussed earlier, we identified TLR5 as a major player in the con-
trol of Hp infections. Using microarrays, we could further
demonstrate that Hp induced known TLR5-specific cytokines
and chemokines including CCL2, CXCL1, CXCL10, CCL20,
interleukin (IL)-32, IL-17F, and others (Pachathundikandi
et al., 2019). This is especially appealing because an operating
CCL2/CCR2 pathway in the infected mucosa, attracting the
infiltration of monocytes and macrophages, is fully obliged for
Th1 immunity against Hp (Arnold et al., 2017). In fact, the inac-
tivation of CCR2 phenocopies major characteristics of TLR5
deficiency such as hyper-colonization and decreased Th1 reac-
tions, but regular Th17 responses (Pachathundikandi et al.,
2019). This suggested that one key effect of TLR5 function in
the gastric epithelium may be the recruitment of the aforemen-
tioned cells, followed by protective T cell responses. We then
found that CagL contains a D1-like motif (DLALLKAN) recog-
nized by TLR5 (Pachathundikandi et al., 2019). Genetic intro-
duction of the DLALLKAN sequence of CagL in Hp flagellin
restored its potential to stimulate TLR5, confirming that the
T4SS with CagL contains a functional D1 mimetic sequence
that can bind to and activate TLR5. However, mutation of the
cagL gene did not fully abolish TLR5 activation by Hp, leading
to the hypothesis that there exists a second TLR5 activating
factor. Here, we identified a TLR5 agonist of this pathogen. Us-
ing a series of molecular techniques, we show that CagY can
activate TLR5.2 Cell Reports 32, 108159, September 15, 2020RESULTS
Worldwide Hp Strains Activate TLR5, Not Coupled to
Effector Molecule Secretion
To investigate whether a wide collection of clinical Hp strains can
activate TLR5, we infected HEK293 reporter cells. In these re-
porter assays, the WT HEK293 cells (parental control), which
are inherently devoid of most innate immune receptors, were sta-
bly expressing human TLR5 (TLR5+) and transiently a luciferase
reporter for the pro-inflammatory transcription factor nuclear fac-
tor kB (NF-kB) (Andersen-Nissen et al., 2005; Forstneric et al.,
2017; Rad et al., 2009). The results show that T4SS-positive
strains from Africa, Europe, Asia, Australia, North America, and
South America specifically activated NF-kB in TLR5+ cells but
not in the parental control (Figures 1A and 1B). We next infected
these TLR5 reporter cells with isogenic mutants of well-known
virulence genes generated in two strains: G27 and P1. Whereas
the inactivation of virulence genes DflaA, DvacA, DnapA, Dggt,
DkatA, Dcgt, and DureA/B or well-described adhesins DbabA,
DsabA, DalpA/B, DoipA, and DhopQ did not terminate TLR5 acti-
vation, the loss of structural T4SS genes DcagL or DcagY down-
regulated TLR5 activation significantly (Figures 1C and 1D; Fig-
ure S1A). Interestingly, strains defective in translocated effector
molecules such as Dslt (peptidoglycan synthesis), DgmhA
(ADP-heptose synthesis), orDcagA (CagA delivery) also activated
TLR5 like WT Hp (Figures 1C and 1D). Thus, TLR5 activation by
the T4SS is not coupled to known effectormolecule translocation.
TLR5 activation by Hp WT and isogenic mutants was
confirmed by a second method using the specific SEAP
(secreted embryonic alkaline phosphatase) HEK293-TLR5 re-
porter system. In this assay, HEK293 cells stably express both
the human TLR5 expression vector and theNF-kB/alkaline phos-
phatase-1 (AP-1)-linked SEAP reporter (TLR5+), or as control,
cells are stably transfected with the NF-kB/AP-1 SEAP reporter
alone (parental). The results show similar TLR5 activation levels
by Hp as compared to the aforementioned reporter assay and
document the reliability of the data (Figure 1E, top). Control blots
against CagY, CagL, and FlaA validate that similar amounts of
each protein are expressed in the various mutant strains (Fig-
ure 1E, bottom). In agreement with previous studies (Pham
et al., 2012), we have observed that the CagL signal was usually
slightly diminished in the DcagYmutant bacteria (Figure 1E, lane
16; see also Figures 3D and S6D); however, this rather minor
decrease cannot account for the overall reduction of TLR5 acti-
vation by Hp.
As further controls, pre-treatment of Hp with proteinase K,
paraformaldehyde, or heat inactivation led to complete loss of
TLR5 activation (Figure S1B). This suggested that the TLR5 acti-
vators are of protein nature. Infection of HEK293 reporter cells in
the presence of penicillin/streptomycin or chloramphenicol also
suppressed TLR5 activity significantly, implying that live bacteria
and protein biosynthesis are required (Figure S1B). We could also
exclude that the TLR5 activating factors are secreted in the cul-
ture supernatant, because preparations of bacteria-free superna-
tants did not induce TLR5 activity (Figure S1B). Instead, we noted
that infection with single DcagL and DcagY mutants produced
some TLR5 background activity, whichwas abolished in amutant
lacking the entire cagPAI (Figure 1E; Figure S1A). We therefore
Figure 1. Stimulation of TLR5 by Worldwide Hp Strains
(A) Hp strains from different continents display a functional T4SS permitting CagA delivery and phosphorylation. Gastric AGS cells were infected in parallel as
control.
(B) Activation of TLR5 in HEK reporter cells was quantified using NF-kB luciferase reporter gene assays. Data are represented as mean ± SEM.
(C) CagA translocation and phosphorylation in AGS cells with T4SS-positive Hp strain G27 involve functional cagA, cagY, and cagL but not flaA, slt, and gmhA
genes.
(D) Activation of TLR5 in HEK cells using NF-kB luciferase reporter assay depends on functional cagY and cagL. Data are represented as mean ± SEM.
(E) SEAP reporter assay of TLR5+ and parental cells infectedwith strain P1 and isogenicmutants of various known virulence genes. The results confirm thatDcagL
and DcagY play a role in TLR5 activation but not other T4SS-independent virulence genes. Data are represented as mean ± SEM.
(F) IP of cell lysates using a-TLR5 antibodies revealed that CagY andCagL interact with TLR5 on TLR5+ cells but not other cagPAI proteins as control. The data are
representative of three independent experiments.Significant differences were defined by p% 0.05 (*), p% 0.01 (**), p% 0.001 (***) and p% 0.0001 (****). n.s. not
significant
See also Figure S1.




Figure 2. T4SS-Pilus Associated Protein CagY of Hp Can Directly Bind to TLR5
(A) Co-localization of Hp (GFP, green) with TLR5 (red) as judged by confocal immunofluorescence microscopy of parental and TLR5+ HEK293 cells counter-
stained with DAPI (blue). Arrows indicate TLR5 signals in proximity to Hp. Dotted lines indicate the cell periphery. Scale bars represent 5 mm.
(B) Schematic domain structure of the CagY protein. The shown C-terminal (C-term) B10 domain of the CagY protein shares homology with Agrobacterium
tumefaciens VirB10. CagY contains two large repeat regions, NRR (red) andMRR (green). Amino-acid positions and purified fragments from twoHp strains (Q86A
and 13A) are indicated.
(legend continued on next page)






OPEN ACCESSproposed that CagL and another yet unknown cagPAI protein
may bind cooperatively and activate TLR5 upon Hp infection.
CagY Is an Agonist of TLR5
To identify a second bacterial binding partner of TLR5, HEK293
reporter cells were infected with the same strains as in Figure 1C,
followed by immunoprecipitation (IP). Using TLR5-specific anti-
bodies, equal quantities of TLR5 have been precipitated (Fig-
ure 1F, top). Re-probing of the blot showed a strong signal for
CagL, and also CagY, but not for the other cagPAI proteins that
were analyzed, including CagA, CagX, CagE, or FlaA as controls
(Figure 1F). This implies that both CagL (Pachathundikandi et al.,
2019) and CagY (this study) localize to the surface of the bacteria,
where they can interact with TLR5. As the expression of both
CagL and CagY proteins is important for T4SS-pilus formation,
there are no or only weak signals of these proteins in the IPs of
corresponding mutants. To corroborate the findings on CagY,
we deleted the cagY gene in Hp and complemented it with WT
cagY or introduced a second cagY gene in WT bacteria, followed
by monitoring TLR5 activity in infected HEK293 reporter cells.
Importantly, the results show that complementation of cagY in
the mutant restored TLR5 activation, while overexpression
through two cagY gene copies even enhanced this response
significantly (Figure S1C). In addition, we utilized Shigella flexneri,
another gastrointestinal pathogen that lacks a flagellin gene and,
therefore, avoids its recognition by TLR5 (Steiner, 2007).We elec-
troporated S. flexneri with a shuttle plasmid expressing cagY or
vector without insert. Infection of HEK293 reporter cells revealed
a robust TLR5 activation when cagY is expressed but not in con-
trol bacteria (Figure S1D). These experiments further provide ev-
idence that CagY is a strong TLR5 agonist.
The Middle Repeat Region of CagY Binds to and
Activates TLR5
Confocal immunofluorescence microscopy was then used to
assess how TLR5 expression affects Hp binding to HEK293
cells. Interestingly, TLR5 expression in HEK293 was required
for strong binding of WT Hp and revealed a clear co-localization
of bacteria with TLR5 signals, which was not seen with DcagY
mutants (arrows in Figures 2A and S2). This was confirmed by
cell-binding assays (Kwok et al., 2002) in a time course, indi-
cating that TLR5 expression was needed for effective attach-
ment of WT compared to DcagY mutant to HEK293 cells (Fig-
ure S3A). We then examined the interaction of fluorescence-
labeled Hp with TLR5 by live-cell imaging (Aspholm et al.,
2006). Both WT Hp and DcagY mutant showed subtle fluores-(C) Coomassie-stained gel of purified CagY fragments.
(D) Protein binding assay. The indicated recombinant CagY fragments, and GS
incubation with recombinant TLR5.
(E) Densitometric quantification of TLR5 binding to the immobilized CagY and co
(F) NF-kB activity in TLR5+ and parental cells treated with 20 nM of the indicated
(G) Dose-response curves of NF-kB activity in TLR5+ and parental cells treated wi
Q86A, respectively. As control, recombinant GST (rGST) protein did not activate
(H) Specific blocking of NF-kB stimulation in TLR5 reporter cells by recombina
neutralizing antibodies. Antibody concentrations are given at the top. CagY- or r
manner. a-hTLR2 antibody treatment served as negative control. All data are rep
mean ± SEM. Significant differences were defined by p % 0.05 (*), p % 0.01 (**),
See also Figure S2.cence signals and binding affinity of parental cells. Conversely,
WT but not DcagYmutant Hp attached firmly to TLR5+ cells (Fig-
ure S3B). These data demonstrate that expression of TLR5 al-
lows binding of Hp to TLR5+ cells, with CagY serving as a ligand
for TLR5 at the bacterial surface.
Theaforementionedobservationswere further substantiatedby
in vitro binding assays. The proposed domain structure of CagY
shows a tripartite organization, comprising the N-terminal repeat
region (NRR) followed by the middle repeat region (MRR) and
the C-terminal VirB10 domain (B10), which are separated by two
predicted transmembrane (TM) domains (Figure 2B). This led to
a hairpin-like model in which the N and C termini are located in
the cytoplasm, while the MRR domain is exposed to the extracel-
lular space (Rohde et al., 2003). Although more recent observa-
tions have superseded this topology (Chandran et al., 2009,
Chunget al., 2019), it has been clearly demonstrated thatMRR re-
peats are associated with the sheathed Cag pilus and are, there-
fore, surface exposed in the mature Cag T4SS complex (Rohde
etal., 2003, Jiménez-Sotoet al., 2009).We therefore hypothesized
that the MRR should be accessible at the cell surface and might
interact with TLR5. To test this idea, we purified the recombinant
His-tagged MRR from two Hp strains, 13A and Q86A (Figure 2C).
As negative controls, we included the C-terminal region of CagY
(glutathione S-transferase [GST]-tagged) and purified GST alone,
and we included Salmonella FliC as positive control. Equal
amounts of these proteins were spotted on a membrane and
probedwith recombinant TLR5 (rTLR5) (Yoon et al., 2012). The re-
sults show that both MRR fragments bound rTLR5 and activated
TLR5 on HEK293 reporter cells with strong intensity, similar to
the FliC positive control (Figures 2D–2F). These binding properties
correlated perfectly with their capabilities to activate NF-kB in
TLR5+ cells in a dose-response curve, utilizing GST protein as
negative control (Figure 2G). Using AAT Bioquest (https://www.
aatbio.com), the half maximal effective concentration (EC50)
values were determined to be 50 nM and 55 nM for rCagY-MRR
(13A) and rCagY-MRR (Q86A), respectively. In addition, MRR-
mediated activation of TLR5 on HEK293 cells was inhibited by
adding function-blocking antibodies against TLR5 in a dose-
dependent manner, but not with a control antibody against TLR2
(Figure 2H). This confirms that the MRR domain of CagY can
directly and specifically bind to rTLR5 similar to Salmonella FliC.
Peptide Arrays Reveal Five TLR5 Binding Sites in the
Repeat Regions of CagY
To investigate which CagY motifs can interact with TLR5, we
performed peptide arrays as described (Beutling et al., 2008;T and Salmonella FliC as control, were immobilized on Dotblots, followed by
ntrol proteins.
CagY and control proteins.
th the specified amounts of indicated CagY-MRR proteins from strains 13A and
TLR5 as expected.
nt Hp CagY and Salmonella FliC (20 nM each) in the presence of a-hTLR5
FliC-induced NF-kB activation was inhibited by a-hTLR5 in a dose-dependent
resentative of at least three independent experiments and are represented as
p % 0.001 (***), and p % 0.0001 (****). n.s. not significant.





































































































































(legend on next page)






OPEN ACCESSConradi et al., 2012a). For this purpose, overlapping 15-mer pep-
tides covering the entire CagY sequence were spotted on two
membranes, comprising the NRR and MRR (membrane-1) and
C terminus (membrane-2), which were probed with rTLR5.
Remarkably, rTLR5 bound strongly to five regions of CagY in
membrane-1 (Figure 3A, yellow circles; Figure S4), while the
CagY C terminus on membrane-2 revealed no specific signals
(Figures S5A–S5C). As control, these peptides were probed
again with rTLR5 on Dotblots, together with control peptides,
and confirmed the aforementioned peptide array results (Fig-
ure 3B). Interestingly, for three clusters of peptide array hits
(comprising motifs 1, 2, 3, and 4), TLR5-interacting peptides
share the same sub-sequences; peptides 28–31 share
‘‘KKARKL,’’ peptides 80–82 share ‘‘KSSRFSKDR,’’ and peptides
317 and 391–393 share ‘‘LQKKVLAKE,’’ providing good confi-
dence that these independent peptide hits are specific and
that the minimal sequences are relevant to TLR5 interaction.
To further verify these findings and validate a key role of CagY
in TLR5 recognition, we mutated the cagY gene in Hp and com-
plemented it with either WT cagY or five deletion mutants in each
of the identified TLR5 binding sites (Figure 3C). The expression of
eachCagY variant was confirmed bywestern blotting (Figure 3D,
top). Tomonitor TLR5 activation, NF-kBactivity was quantified in
infected HEK293 reporter cells. The CagY D82–105 and D1171-
1191 mutants revealed the strongest defects in TLR5 activation,
while D238–258, D370–384, and D949–963 mutants had inter-
mediate levels (Figure 3D). This confirms the identification of
five TLR5 binding sites in CagY, with significant importance in
TLR5 activation. As control for T4SS functionality in all strains,
we examined T4SS-pilus formation in mutated CagY variants.
Field emission scanning electron microscopy (FESEM) revealed
proper T4SS-pilus expression for WT Hp and in all five specific
CagY deletion variants but not in the entire DcagY deletion
mutant as expected (Figure 3E, arrows). This excludes the pos-
sibility of polar effects that may occur during genetic introduction
of the CagY mutants.
Next, we made a series of larger CagY deletion mutants,
including the entire NRR, MRR, and C-terminal B10 domains,
as well as two control deletions of 15 amino-acid stretches
each in the spacer region between the MRR and B10 domains
(Figure S6A). The resulting protein variants are expressed with
the expected sizes on western blot gels (Figure S6B). Remark-
ably, while the control deletion mutants D1602–1616 and
D1659–1673 activated TLR5 like WT Hp or the complemented
WT cagY strain, the DMRR and DB10 mutants revealed signifi-
cantly less TLR5 activity, similar to the DcagY entire deletion,Figure 3. Mapping of CagY Interaction Sites with TLR5 and Role durin
(A) Peptide arrays of overlapping 15-mer CagY peptides were co-incubated with
vealed binding of TLR5 to five areas on the array that are highlighted with yellow
(B) The shown CagY peptide sequences are involved in TLR5 binding and were re
to bottom comprise ELNEEDDQENNEYQE, CVSRARNEKEKKE, KALGGNKKDDD
(C) Schematic structure of the CagY protein and generation of the indicated dele
(D) Importance of TLR5 binding sites in CagY for Hp-triggered, luciferase-based N
independent experiments and are represented asmean ± SEM. Significant differe
(****). n.s. not significant.
(E) FESEM of T4SS-pilus formation of the indicated Hp strains after 12 h infectio
represent 300 nm.
See also Figures S3,S4,S5,S6, and S7.with intermediate levels induced by the DNRR mutant (Fig-
ure S6C). These results further corroborate our findings that
NRR and MRR sequences play roles in TLR5 activation but also
that the B10 domain is involved. The latter can be explained by
CagY being a component of the T4SS core complex that is
located mainly within the periplasm, and a portion of CagY that
localizes to the outer membrane (Chung et al., 2019). Thus, it
canbeassumed that deletion of theB10domain abrogates expo-
sure of the NRR and MRR domains to the extracellular space as
well as T4SS functionality. Control blots against CagL, FlaA, and
GAPDH confirm that similar amounts of each protein are ex-
pressed in the different mutant variants (Figure S6D).
CagY Sequence Analysis and Distribution of TLR5
Binding Sites in Worldwide Hp Strains
In the following experiments, we have investigated 19 available
T4SS-positiveHp strains with fully sequenced CagYs (Figure S7;
Table S2). TLR5+ and parental HEK293 reporter cells were in-
fected with each of these 19 Hp strains. Activation of TLR5 was
strong with all strains, as quantified by NF-kB luciferase reporter
assays (FigureS7, right side). Sequence analysis showed that the
individual TLR5 binding motifs 1–5 are present in each of these
CagY proteins; however, they vary considerably in their positions
along the polypeptide as well as in the distance from each other,
as highlighted with dotted lines in Figure S7. For example, motif 2
was predominantly found at the C-terminal end of the NRR
domain, while in one strain (Lithuania75), this motif was in the
MRR domain. On the other hand, motif 3 was often observed at
the N terminus of the MRR domain, while in some strains (35A
and Gambia94/24), it was placed in the space region between
the NRR and MRR domains. Thus, variability exists concerning
the position of motifs 1–5 in the CagY polypeptide chain.
In addition, a database search of, altogether, 48 deposited
CagY sequences disclosed a remarkable conservation of the
overall CagY domain structure and presence of all TLR5 binding
motifs 1–5 among Hp strains from different continents (Figures
4A and 4B) but no similarity to D1 or D0 motifs of known TLR5
activator flagellins from Salmonella or Vibrio (Andersen-Nissen
et al., 2005). Structural investigation of CagY revealed that the
MRR is almost exclusively composed of short repeats
comprising 35 residues. These repeats, which are character-
istic for all known CagYs, were termed DC-EC repeats based
on the occurrence of conserved DC- and EC-sequence motifs.
The 3D structure of these repeats is yet unknown, but they
were shown by circular dichroism (CD) spectroscopy to exhibit
a high content of helical secondary structure (Delahay et al.,g Infection
recombinant zebrafish TLR5 (His-tagged). Probing with a-His antibodies re-
circles. White spots indicate peptide spots without TLR5 binding.
-spotted on Dotblots and re-probed with rTLR5. Five control peptides from top
KEKS (fromCagY), EGKLKIEQEKQNIR, and RSLEQSKRQYLQER (fromCagL).
tion mutants.
F-kB activity in TLR5+ and parental cells. The data are representative of three
nces were defined by p% 0.05 (*), p% 0.01 (**), p% 0.001 (***), and p% 0.0001
n of TLR5+ cells. Examples of T4SS-pili are indicated with arrows. Scale bars
Cell Reports 32, 108159, September 15, 2020 7
Figure 4. Conservation of TLR5 Binding Sites in CagY of Worldwide Hp Strains
(A) Sequence comparison of five identified TLR5 binding motifs in CagY. Forty-eight CagY protein sequences were retrieved from GenBank and used in the
alignment (Table S1). The protein sequences of the following reference strains were used: HspAmerind: v225d, Shi112, Shi169, Shi417, Shi470, Puno135,
Puno120, and Sat464; hpAsia2: BM012A, BM012S, UM032, UM299, UM298, UM066, UM037, PTN63, NIAS36, MER98, SBY192, MKS55, and 3K; hspEAsia:
Oki898, Oki422, Oki102, Oki112, OK310, OK113, F16, F57, F32, F30, 35A, and 51; HspSouthIndia: SNTP49 and India7; hpAfrica: J99, J166, and PeCan18;
hpEurope: ELS37, B8, Lithuania75, SJM180, P12, 26695, Rif1, Rif2, FDA_299, and PMSS1.
(B) Phylogenetic analysis of five identified TLR5 binding motifs in CagY. The major clade branch points on the tree were labeled with red arrows as follows: a.
hpAfrica; b. an intermingled clade between hpEurope and hpAsia strains; c. an intermingled clade between hpAsia, hspEAsia, and some strains from hpAsia2; d.
hspAmerind strains.
(C) Repetitive segments in CagY. The y axis indicates the coiled-coil propensity, with high bars noting a strong tendency to form coiled coils. Scanning was
performed with three different window lengths of 14 (green), 21 (blue) and 28 (red) residues.
See also Figure S7 and Table S1.
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OPEN ACCESS2008). More detailed sequence analyses revealed the presence
of a large number of repetitive segments in the NRR and MRR
domains. These repeats conform the sequence pattern of coiled
coils (Figure 4C) but are also equally compatible with other
closely related repeats; most notably, the tetratricopeptide re-
peats (TPRs) (Delahay et al., 2008).
Mapping of TLR5 Domains Required for Activation byHp
TLR5 consists of a large extracellular domain responsible for
ligand binding, a TM segment, and an intracellular TIR domain
for downstream signaling (Figure 5A, top). The extracellular
domain is composed of >20 leucine-rich repeats (LRRs) forming
a concave surface (Yoon et al., 2012). The first 10 LRRs play a
major role in the interaction with FliC and were termed as inter-
faces A andB (Yoon et al., 2012). Bindingmainly occurs between
LRR9 of TLR5 and the D1/D0 domains of FliC, as indicated in
crystal structures (Song et al., 2017). After docking by FliC, two
TLR5-FliC heterodimers form a complex, which enables
signaling via the TIR domain (Yoon et al., 2012). To investigate
the role of the different TLR5 domains for its activation by Hp,
we generated a series of FLAG-tagged deletion mutants in
both the intracellular and extracellular domains of TLR5 (Fig-
ure 5A). Transfection into HEK293 parental cells and western
blotting confirmed that these constructs were expressed at
similar levels (Figure 5B). TLR5 activation by Hp infection was
monitored under the same conditions (Figure 5C). All mutants re-
vealed significantly decreased NF-kB activity compared to WT
TLR5. Interestingly, the deletion of interface A had a slightly
greater impact for Hp-triggered NF-kB activation than the dele-
tion of interface B, which contains LRR9, the main binding spot
for FliC. Together, both interfaces A and B are crucial for the
recognition of Hp by TLR5, while interface A seems to be more
important.
TLR5 Is Overexpressed in Patients with Severe Gastric
Diseases
Finally, we examined immunohistochemically whether the afore-
mentioned findings are of in vivo relevance in patients with se-
vere gastric diseases (Figures 6A–6G; n = 56). Remarkably, while
antrum biopsies from healthy non-infected individuals showed
very little or no TLR5 staining (Figure 6A), TLR5 signals appeared
upon infection and gradually increased with the grade of Hp
colonization and severity of inflammation in the gastric mucosa,
as classified by the updated Sydney System (Dixon et al., 1996).
Staining for TLR5+ was strongly upregulated in patients with Hp-
associated lymphocytic gastritis (Figure 6B); low-grade B cell
lymphoma of the MALT type (Figure 6C); autoimmune gastritis
(Figure 6D); and, according to Laurén classification (Lee et al.,
2018), the intestinal type of gastric adenocarcinoma (Figure 6E),
while the signals were significantly reduced in Hp-negative pa-
tients with the diffuse type of gastric carcinoma (Figure 6F).Figure 5. Deletion Mutagenesis Revealed the Importance of TLR5 Dom
(A) Schematic presentation of TLR5 deletion mutants produced in this study.
(B) Equal expression of these constructs in HEK293 parental cells was confirmed
(C) TLR5 activation of WT Hp 7.13 infected versus uninfected cells was quantifi
antibodies served as loading control. The data are representative of three indepen
were defined by p % 0.05 (*), p % 0.01 (**), p % 0.001 (***), and p % 0.0001 (****
10 Cell Reports 32, 108159, September 15, 2020TLR5+ staining was mainly detected in epithelial cells, granulo-
cytes, and plasma cells within the lamina propria, while goblet
cells (intestinal metaplasia) were devoid of TLR5. Immunoreac-
tive scoring according to Remmele and Stegner (1987)
confirmed that TLR5 expression is significantly induced by Hp
infection and coincides with the grade of inflammation and
gastric malignant progression in patients (Figure 6G).
DISCUSSION
The major Hp virulence factor determining whether infection
causes gastric disease or asymptomatic colonization is the
Cag T4SS, a syringe-like pilus exposing the CagL and CagY pro-
teins at its surface. Both proteins are essential for T4SS function-
ality and exploit integrin receptors (Kwok et al., 2007; Jiménez-
Soto et al., 2009; Conradi et al., 2012b; Koelblen et al., 2017;
Naumann et al., 2017). Recently, we found that CagL also binds
and activates TLR5 (Pachathundikandi et al., 2019). Surprisingly,
here, we identified that CagY could also bind and activate TLR5
for increased host responses against infection. This is especially
remarkable, because TLR5 has been repeatedly excluded from
playing a role in Hp infections due to the low intrinsic activity of
its mutated flagellin (Andersen-Nissen et al., 2005; Forstneric
et al., 2017; Song et al., 2017; Rad et al., 2009).We could confirm
that Hp avoids the recognition of FlaA but instead evolved CagY
and CagL known to be present at the tip of the T4SS-pilus
(Rohde et al., 2003; Kwok et al., 2007) as TLR5 ligands, thereby
regulating host immunity when required (Pachathundikandi
et al., 2019). We propose that an evolutionary shift away from
FlaA confers Hp with the opportunity to avoid permanent TLR5
activation by exposing or hiding CagY (Figures 7A and 7B).
These ideas would be in line with previous observations that
T4SS-pilus function can be turned on and turned off through
recombination in the cagY gene (Barrozo et al., 2013). The
consequence of such a ‘‘hide and seek’’ characteristic of TLR5
ligands in Hp may deregulate or hyper-regulate host immunity
to control its own infection, bacterial competitors, and cause se-
vere immuno-pathologies (Figures 7A and 7B).
CagY consists of two defined repeat domains, NRR andMRR,
which harbor extraordinary numbers of direct DNA repeats pre-
dicted to be involved in gene rearrangements. While NRR is yet
entirely uncharacterized, MRR has a regular disposition of six re-
petitive motifs, which invariably yield in-frame insertions or dele-
tions (Liu et al., 1999; Aras et al., 2003, Delahay et al., 2008).
These events lead to the generation of differences in CagY pro-
tein size, which appears to be sufficient to cause gain or loss of
T4SS function (Barrozo et al., 2013). In line with this, the cancer
chemopreventive agent a-difluoromethylornithine (DFMO) was
shown to reduce Hp-mediated gastric cancer incidence in ger-
bils by causing MRR mutations in cagY (Sierra et al., 2019).
TheMRR comprises two acid-stable and thermo-stable a-helicalains in NF-kB Activation during Infection with Hp
with a-FLAG-Tag antibodies.
ed by NF-kB luciferase reporter gene assay. Western blotting with a-GAPDH
dent experiments and are represented as mean ± SEM. Significant differences
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Figure 7. Model of CagL/Y-Dependent Hp
Pathogenesis by TLR5-Stimulated Immune
Responses in the Host Controlling Inflam-
mation and Bacterial Colonization
(A) Hp expresses an unresponsive flagellin (‘‘OFF’’
status) and instead expresses the T4SS-pilus
surface proteins CagL and CagY, which emerged
as trigger of TLR5 activation, when T4SS-pili are
expressed (‘‘ON’’ status).
(B)However, T4SS-pilus functionscanbe turnedon
and turned off through recombination in T4SS
proteins (Barrozoetal., 2013). ThisshiftprovidesHp
with the ability to avoid permanent TLR5 activation
byhidingCagLandCagY in theT4SS ‘‘OFF’’ status.
In this way, by engaging TLR5,Hp is able to control
the host inflammatory response, bacterial com-
petitors, and its own colonization. Figure adapted
from Pachathundikandi et al., 2019.
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OPEN ACCESSstructural motifs, most of which occur in tandem arrays of 1–6 re-
peats flanked by single copies of a second repeat (Delahay et al.,
2008). Distinct motifs revealed hetero- and homomeric interac-
tions, advocating a propensity for uniform assembly of discrete
structural subunits within the larger MRR domain. However,
most of the TLR5 interacting segments mapped by our experi-
ments are located both in the NRR and MRR of CagY. These
findings support our idea that the entire N terminus with the
MRR domain of CagY is exposed to the extracellular space,
and it does not adopt the previously discussed hairpin-like
model (Rohde et al., 2003).
As the C-terminal B10 domain is now known to comprise a
surface localized ‘‘cap’’ of the Cag T4SS (Chung et al., 2019), itFigure 6. Upregulation of TLR5 Expression in the Mucosa of Hp-Infected Patients with Maligna
infected Individuals
Immunohistochemistry of TLR5 expression in gastric biopsies of patients (n = 56). Each dot represents one p
indicated.
(A) Non-infected antrum mucosa revealed very little or no TLR5-positive cells nor pathological changes.
(B–E) Hp colonization of antrum mucosa from patients with (B) lymphocytic gastritis, (C) MALT lymphoma,
gastric adenocarcinoma revealed pronounced cytoplasmatic TLR5 staining of plasma cells and nuclear stai
(F) Antrum mucosa in a diffuse type of gastric adenocarcinoma without Hp colonization showed no TLR5 ex
(G) Quantification of TLR5 staining in the patients described above by ImmunoReactive Score (IRS).
12 Cell Reports 32, 108159, September 15, 2020is reasonable to suggest that CagY may
undergo processing to allow incorpora-
tion of distinct domains into different as-
sembly states. Indeed, we (Figure 1E)
and others (Jiménez-Soto et al., 2009;
Barrozo et al., 2013; Rohde et al., 2003;
Frick-Cheng et al., 2016) consistently
detect multiple distinct CagY protein
bands in western blots in support of
this. It can, therefore, be considered
that the N-terminal TM region (Figure 2B)
might tether the MRR to the inner mem-
brane enabling its extension along the
length of the T4SS-pilus (Chang et al.,
2018), while either or both of the
NRR and B10 domains are liberated inprocessing events to be incorporated in surface-exposed
structures.
Computational motif identification approaches failed to detect
any unique sequence patterns in CagY comparable to those of
the other TLR5 ligands, FliC and CagL. Thus, it appears most
likely that the interaction properties of CagY with TLR5 are gov-
erned by a yet-unknown mechanism. In this context, the obser-
vation of a large repeat region, harboring either coiled coils or
TPRs, may offer a plausible explanation. Both types of repeats
are known to create scaffold structures that allow the recognition
of a large number of structurally diverse interaction partners (Lu-
pas and Bassler, 2017; Perez-Riba and Itzhaki, 2019). Thus, we
suggest that these repeat regions represent scaffold elementsnt Sequelae in the Stomach but Not in Non-
atient. Scale bars represent 100 mm or 200 mm as
(D) autoimmune gastritis, and (E) intestinal type of




OPEN ACCESSimportant for CagY structure and interaction with TLR5. In fact,
coiled coils exhibit heptad periodicity, in which positions 1 and
4 are typically hydrophobic and act as core residues; all others
are usually polar or charged. This feature causes left-handed
supercoiling and allows for knobs-into-holes packing (Lupas
and Bassler, 2017). Packing occurs in a parallel or an antiparallel
fashion (Lupas, 1996) and there exist multitudes of topologies
derived from these basic principles including fibers, levers,
tubes, funnels, sheets, spirals, and rings that may consist of
more than 20 helices (Lupas and Bassler, 2017). Amphipathic
a helices, however, cannot only form coiled coils but also other
types of repeats like the TPRs. TPRs consist of 34 amino acids
and are found in arrays comprising between 2 and 20 repeats
(Perez-Riba and Itzhaki, 2019). Packing of the individual TPRs
against each other results in coiled and superhelical structures.
These scaffold structures can mediate interactions with a large
variety of different partners, ranging from short linear peptide
motifs to large globular protein domains (Perez-Riba and Itzhaki,
2019). Therefore, we propose that the insertion/deletion of a re-
petitive segment in CagY may alter the intermolecular pairings
within the repeat region, thereby affecting the solvent accessi-
bility of individual segments. Such a mechanism might explain
how CagY insertions/deletions, which do not directly affect the
interacting segments, may alter TLR5 binding properties of
CagY.
We have also characterized the TLR5 domains required for
activation and signaling by CagY/Hp. It was not surprising that
the deletion mutant of TLR5 dimerization domain impaired Hp-
induced activation due to the known critical role in signaling.
TLR5 interface regions A and B are critical in FliC D1-domain-
mediated NF-kB activation due to the presence LRR9 in B region
(Yoon et al., 2012). Thus, for the TLR5 and CagY interaction,
interface A appears to be more important compared to interface
B. As the Hp T4SS-pilus became the TLR5 interaction partner,
the whole scenario of TLR involvement in Hp infection and con-
trol changed completely. Previous studies showed the important
roles of TLR2, TLR4, TLR9, and TLR10 in Hp infection (Kim et al.,
2013; Koch et al., 2015; Pachathundikandi and Backert, 2016;
Nagashima et al., 2015; Varga et al., 2016). TLR2 appeared to
be involved in both pro- and anti-inflammatory responses in
Hp infection (Rad et al., 2009). However, the role of TLR4 in Hp
infection is still controversial and not concludedwell (Pachathun-
dikandi et al., 2015). The function of TLR9 and TLR10 was also
associated with the induction of anti-inflammatory responses
(Nagashima et al., 2015; Varga et al., 2016). Thus, TLR5 activa-
tion by T4SS-pilus proteins CagY and CagL becomes important
on controlling the gastric microbiota and favor Hp growth in the
stomach. This gives Hp a unique advantage to survive in this
niche and persist for long periods, which results in various asso-
ciated pathologies.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human AGS and HEK293 cells
Embryonic kidney HEK293 cells (parental WT, ATCC CRL-1573), HEK293 cells stably expressing human TLR5 and SEAP reporter
cells (hTLR5+) with parental control were obtained from InvivoGen (San Diego/USA). Both cell lines were cultured in DMEM (Dulbec-
co’sModified EagleMedium) supplementedwith 4mML-glutamine, 4.5 g/L D-glucose, 110mg/L sodiumpyruvate and 10% fetal calf
serum (FCS) (Invitrogen, Carlsbad/USA). The gastric epithelial adenocarcinoma cell line AGS (ATCC CRL-1739) was cultured in
RPMI-1640 medium containing 10% FCS obtained from GIBCO (Paisley/UK), maintained in tissue culture flasks (75-cm2). The me-
dium of all cell lines was supplemented with a 1% antimycotic and antibiotic cocktail (Sigma-Aldrich), and HEK293 cells additionally
with 10 mg/mL blasticidin (InvivoGen). Before infection, the cells were seeded into Petri dishes or 12-well plates (Greiner-Bio-One,
Germany) containing medium free of antimycotics and antibiotics. Cultivation was performed in 37C incubators with 5% (v/v)
CO2 until the monolayers reached a confluence of 70%–90%.
Bacterial growth, gene mutagenesis and infection studies
We employed a list of well-knownHp strains which comprise the cagPAI-positive wild-type (WT) strains P1, G27, Gam94-24, HPAG1,
IND7, TN2-GF4, 11638, B128, Shi470, 7.13 and others (Kwok et al., 2007; Pachathundikandi et al., 2011, 2019; Varga et al., 2016, see
Key Resources Table). Isogenic Hp mutants were produced using the insertion of chloramphenicol or kanamycin resistance cas-
settes, respectively, by established standard protocols (Backert et al., 2001; Moese et al., 2004). For genetic complementation of
cagY, the cagY gene on the chromosome of strain 7.13 was first replaced by a cat-rpsL cassette, resulting in streptomycin-sensitive
(rpsL encodes dominant streptomycin sensitivity) and chloramphenicol-resistant transformants as described (Barrozo et al., 2013).
Then, the WT cagY gene of strain PMSS1 and deletion mutants shown in Figure 3C were used to replace the cat-rpsL cassette by
natural transformation, leaving an unmarked deletion. Contra-selection was used to screen for streptomycin-resistant Hp with the
various cagY variants. For the generation of WT Hp expressing two cagY gene copies, the cagY gene of strain 26695 was fused
withNdeI and SalI restriction sites at the 50 and 30 ends, respectively, and placed under the flaA gene promotor in theE. coli/Hp shuttle
vector pSB14 (Backert et al., 2005). All Hpmutants were checked by re-sequencing to confirm the correct construction, and protein
expression was verified by western blotting. All Hp strains were cultivated on GC agar plates containing horse serum (10%, Biowest,
Nuaillé/France), nystatin (1 mg/mL), vancomycin (10 mg/mL) and trimethoprim (5 mg/mL), and the mutant colonies were selected by
adding chloramphenicol (4 mg/mL), streptomycin (10 mg/mL) or kanamycin (8 mg/mL), respectively. All antibiotics were purchased
from Sigma-Aldrich (St. Louis/USA). Hp growth was achieved for 2 days at 37C in anaerobic jars with CampyGen gas mix pouches
(Oxoid, Wesel/Germany). For expression of CagY in Shigella flexneri, cagY was placed under the S. flexneri htrA gene promoter as
cloned in the single NdeI site containing the start codon of cagY. This construct was electroporated in S. flexneri WT strain 15.4.
Expression of CagY was confirmed by western blotting. S. flexneri and Hp were grown on agar plates, harvested, and resuspended
in PBS (Phosphate Buffered Saline, pH 7.4) using sterile cotton swabs (Carl Roth, Karlsruhe/Germany). The number of bacteria was
calculated as optical density (OD, at 550 nm) in an Eppendorf spectrophotometer, and confirmed by counting the CFU (colony-form-
ing units) on agar plates. The AGS and HEK293 cells grown in medium without antimycotics and antibiotics were infected with
S. flexneri and Hp at a MOI (multiplicity of infection) of 25 for 8 h in all experiments. In the mock control samples, we added an equal
amount of PBS to the host cells.
METHOD DETAILS
Control treatments and preparation of cell-free bacterial culture supernatants
For control experiments, Hp were resuspended in PBS as described above and either treated with (i) proteinase K (10 mg/mL) for
10 min at 60C, (ii) fixed with paraformaldehyde (PFA, 4%) for 10 min at 37C or (iii) heated for 10 min at 95C. Before adding to
the HEK293 cells, proteinase K was inactivated by adding PMSF (5 mM), and PFA-fixed bacteria were washed two times in PBS
by centrifugation steps at 4,000 rpm. As other controls, penicillin/streptomycin (10 mg/mL) or chloramphenicol (20 mg/mL) were added
to the HEK293 cells followed by infection. Furthermore, culture supernatants were prepared from Hp 7.13 WT grown for 24 h in BHIe5 Cell Reports 32, 108159, September 15, 2020
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OPEN ACCESSliquid broth using sterile filters (0.21 mm). The protein concentration in the supernatants was measured using Bradford protein assay
reagent (Bradford, Hercules/USA) and 5 mgwere added to the cells. Absence of live bacterial CFU in the supernatants was confirmed
by incubation on GC agar plates for four days.
Generation of CagY and TLR5 deletion constructs
The WT cagY gene of Hp strain PMSS1 (NCBI Protein accession number: AQM72202) as well as three deletion mutants (D370-384,
D949-963 and D1171-1191, Figure 3C) in TLR5 binding sites were chemically synthesized by Geneart (Thermofisher Scientific,
Waltham/USA). The CagY D82-105 and D238-258 variants were produced by mutagenesis by PCR. In addition, the WT cagY
gene was retrieved from the genome of Hp strain 26695 (NCBI Nucleotide accession number: AE000511.1), position 554206 to
559989) and was cloned from a full-length PCR product. Three deletion mutants DNRR (amino acids 2-342), DMRR (amino acids
512-1,442) and DB10 (amino acids 1621-1,927) (Figure S6A) were chemically synthesized by Geneart (Thermofisher Scientific,
Waltham/USA). In addition, control deletion mutants (D1602-1616 and D1659-1673) in the spacer region between the MRR and
B10 domains were generated by PCR (Figure S6A). All CagY constructs were complemented into the cancerogenic strain 7.13
(Key Resources Table). In order to determine the impact of different TLR5 domains on the NF-kB expression level, we also generated
TLR5 deletion mutants as shown in Figure 5A. The different mutants and their naming were based on a publication by Yoon et al.
(2012), which elucidated the basis of TLR5 and flagellin binding. Based on this paper, seven different TLR5 deletion mutants were
created by mutagenesis PCR. All used primers are listed in the Key Resources Table. The TLR5 WT sequence was taken from
pcDNA3-TLR5-CFP (Addgene, Watertown, USA) and cloned into the pCMV-3Tag-3a vector (Agilent Technologies) together with
a Kozak sequence. All constructs were approved by conventional DNA sequencing and are listed in the Key Resources Table.
NF-kB luciferase reporter assay
HEK293 TLR5+ and parental control cells (2 3 105/mL) were cultivated in 12-well plates (Greiner Bio-One), followed by 48 h
transfection of 2 mg NF-kB luciferase construct (Viala et al., 2004) with TurboFect reagent using a standard protocol by the supplier
(Thermofisher Scientific, Waltham/USA). The transfected cells were infected with the various Hp strains at MOI = 25 for 8 h or treated
with recombinant CagY fragments, GST or FliC (20 nMolar each) followed by luciferase assay. In brief, the cells were collected in lysis
buffer (25 mM HEPES pH 7.8, 5% Glycerol, 20 mM DTT, 2 mM EDTA and 1% Triton X-100). One portion of the lysate was applied to
determine the protein concentration of each lysate. This wasmeasured using Bradford protein assay described above. Equal amount
of lysis buffer was used as blank. The other portion was subjected to measure luciferase activity (as Relative Light Units, RLU) in
luciferase assay buffer (25mMHEPES pH 7.8, 5 mM ATP, 15 mMMgSO4 and 0.5 mMD-Luciferin) using the Orion Microplate Lumin-
ometer (Titertek Berthold, Pforzheim/Germany). The RLUs were normalized against the protein concentrations. The overall data are
presented as the ratio between the uninfected mock control value (set as 1) and the values of the infected samples, given as fold
increase (Viala et al., 2004).
SEAP reporter gene assay
TLR5 activation was also examined by using human TLR5/NF-kB/SEAP reporter HEK293 cells (HEK-Blue-hTLR5) and HEK-Blue
Null1 cells (Invivogen) as control. Stimulation of HEK-Blue-hTLR5 cells with a given TLR5 ligand activates NF-kB and alkaline phos-
phatase-1 (AP-1) which induce the production of secreted embryonic alkaline phosphatase (SEAP) (Varga et al., 2016). To perform
the assays, the cells were seeded and infected with H. pylori in 12-well plates as described above. After 24 h of co-incubation, levels
of SEAP were quantified by adding 20 mL of infected cell supernatant (or non-infected cell culture medium as negative control) to
180 mL Quanti-Blue medium (Invivogen) per well into a 96-well plate at 37C for 30min andmeasuring the OD at 620 nmwith amicro-
plate reader (Infinite F200 Pro, Tecan, Grödig/Austria).
Field emission scanning electron microscopy (FESEM)
TLR5+ cells were infected with Hp for 12 h and then fixed with 5% formaldehyde and 2% glutaraldehyde in HEPES buffer (0.1M
HEPES, 0.09 M sucrose, 10 mM CaCl2, 10 mMMgCl2, pH 6.9) and washed with TE buffer (10 mM EDTA, 2 mM EDTA, pH 6.9). Sam-
ples were dehydrated in a graded series of acetone (10, 30, 50, 70, 90, 100%) on ice for 15 min for each step. Samples in the 100%
acetone step were allowed to reach room temperature before another change in 100% acetone. Samples were then subjected to
critical-point drying with liquid CO2 (CPD 300, Leica, Wetzlar, Germany). Dried samples were coated with a gold/palladium (80/
20) film by sputter coating (SCD 500, Bal-Tec, Liechtenstein) before examination in a field emission scanning electron microscope
Zeiss Merlin (Oberkochen, Germany) using the Everhart Thornley HESE2-detector and the inlens SE-detector in a 25:75 ratio at an
acceleration voltage of 5 kV. Images were recorded with Zeiss SEMSmart V 6.06 SP2.
Confocal immunofluorescence microscopy
For immunofluorescence staining, TLR5+-transfected and parental HEK293 cells were infected for 6 h with Hp G27 WT and G27-
DcagY mutant expressing GFP from shuttle plasmid pSB14 (Backert et al., 2005). After infection, the cells were fixed with 4%
PFA, permeabilized with 0.1% saponin and blocked with 1%BSA (Tegtmeyer et al., 2017). TLR5 was first immunostained with rabbit
a-TLR5 antibody (Thermo Fisher Scientific, #36-3900) following with secondary Alexa Fluor 633 conjugated goat a-rabbit (Invitrogen,
#A-21070) antibodies. 40,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific) was used for the counterstaining of cell nuclei.Cell Reports 32, 108159, September 15, 2020 e6
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using an oil immersion 100 3 objective (NA 1.4). Excitation/emission of the fluorescence from DAPI, GFP and Alexa Fluor 633 was
proceeded at 405/413–460 nm, 488/496–550 nm, and 633/643–700 nmwavelengths, respectively. The experiments were performed
in triplicates and obtained data were visualized using LAS AF computer software (Leica Microsystems).
LigandTracer real-time fluorescence imaging
Hp G27 WT and its isogenic DcagY mutant were cultivated on horse serum GC agar plates as described above. For labeling, the
bacteria were harvested and resuspended in phosphate buffered saline (PBS, pH 7.4). The labeling of the bacteria with Fluorescein
isothiocyanate (FITC) (Sigma-Aldrich) was performed as described (Aspholm et al., 2006). After the labeling process, the bacteria
were stored at 80C in BHI medium (Oxoid) with 20% glycerol (Carl Roth, Karlsruhe/Germany) until use. The LigandTracer Green
instrument (Ridgeview Instruments AB, Uppsala, Sweden) was utilized tomonitor the interaction ofHp to HEK293 TLR5+ and parental
cells under live-cell conditions in real time. All measurements were performed in a Hera Cell 150i CO2 incubator (Thermofisher, Wal-
tham, Massachusetts, USA) to create experimental conditions of 37C and 5%CO2 suitable for Hp. 24 h before the experiments 23
106 freshly split HEK cells were seeded in a Nunclone Surface Petri dish (Nunc A/S, Roskilde, Denmark) pre-coated with Poly-L-Lysin
(Sigma-Aldrich) using the protocol provided by Ridgeview. One side of the plate was kept cell-free and was used as the background
reference. The cell monolayer was grown to a confluence of 90%, which was confirmed by light microscopy. Before measuring, the
cells were carefully washed three times with DMEM and 10% FCS, and kept in of the same media afterward. The experiments were
done with the ‘‘general assay’’ template which is included into the LigandTracer Control software (Ridgeview Instruments AB). One
hundred mL of FITC-labeledHp of OD600 = 1.0 were given to the cells, after performing a 30min baselinemeasurement. The change in
the fluorescence signal due to the binding of the bacteria to the HEK293 cells wasmonitored over a 90min time course. The plate was
rotated in the device once every 60 s. Each time the fluorescence detector compared the fluorescence signal of the cells to the refer-
ence signal of the opposite untreated part of the plate.
Purification of recombinant CagY fragments
CagY MRR fragments (originating from strains Q86A or 13A) were overexpressed from pET17b with 6xHis-tag (Novagen, Merck
Chemicals Ltd, Darmstadt, Germany) as described previously (Delahay et al., 2008), then purified using Talon resin (BD Biosciences,
Oxford, UK) in a modified two-step protocol, whereby the initial elution fractions were pooled, desalted then re-applied to Talon resin
to remove residual contaminating proteins. Final elution fractions were concentrated and buffer exchanged to 50 mM Tris-HCl, pH
7.0 using Vivaspin centrifugal concentrators (Sigma-Aldrich, Dorset, UK). Expression and purification of GST and GST-CagY C-ter-
minal fusion proteins was performed using an optimized protocol to that described previously (Tegtmeyer et al., 2010). Briefly, cul-
tures were induced at late logarithmic phase with 1 mM isopropyl-b-d-thiogalactopyranoside, with continued incubation for16 h at
room temperature prior to harvest. Re-suspended bacterial pellets were partially lysed by freeze/thaw steps in 20mL PBS containing
protease inhibitors (Roche, Sigma-Aldrich, Dorset, UK), then lysis completed by mild sonication. Lysates were clarified by centrifu-
gation and 0.45 mM filtration prior to incubation with washed Glutathione-Sepharose 4 Fast Flow (GE Healthcare, Buckinghamshire,
UK) for 30 min at 4C. Elution fractions were pooled, concentrated, and buffer exchanged to 50mM Tris-HCl, pH 7.0 as for the 6xHis-
tagged CagY MRR fragments. Purity of all recombinant proteins was estimated to be >95% by Coomassie-Brilliant Blue staining of
SDS-PAGE gels (Figure 2C), and protein concentrations, determined using the BCA protein assay (Pierce, Fisher Scientific, Leices-
tershire, UK), were routinely in the range of 800 mg/mL for the GST proteins and 1 – 1.5 mg/mL for the 6xHis-tagged proteins.
Purification of recombinant TLR5 protein
A fusion protein of zebrafish TLR5 represents the only obtainable form of recombinant TLR5 (rTLR5), which is soluble as an active
receptor for flagellin FliC binding (Yoon et al., 2012). For this purpose, an N-terminal zebrafish TLR5 portion (amino acids 22-390)
was cloned together with a C-terminal portion of variable lymphocyte receptor (VLR from hagfish, amino acids 126-200). Additionally,
rTLR5 was fused with a C-terminal 6xHis-tag and Strep-tag II (WSHPQFEK) for purification as well as a cleavage site for thrombin.
Expression of the construct was performed in Hi5 insect cell system following infection by rTLR5 baculovirus. Biochemical purifica-
tion of rTLR5 was performed using Ni-NTA affinity (QIAGEN) and Strep-Tactin affinity chromatography (IBA Lifesciences) as
described (Yoon et al., 2012). The purified rTLR5 protein was finally dialyzed using a buffer containing 20 mM HEPES (pH 7.4),
1.5 mM b-mercaptoethanol and 150 mM NaCl.
Inhibition of TLR5 with neutralization antibodies
To confirm the specificity of the TLR5 ligands on the HEK293 reporter cell system, specific neutralizing TLR antibodies were utilized.
For this purpose, HEK293 TLR5+ and parental cells were cultured as described above and co-incubated with a-human TLR5
(a-hTLR5) IgA (InvivoGen). This is an established neutralizing monoclonal antibody (mAB) for human TLR5, inhibiting FliC-triggered
TLR5 activity (InvivoGen). The neutralizing capability of these antibodies was evaluated at growing concentrations (25 ng/mL to 1 mg/
mL) as recommended by the supplier. As control, we utilized a TLR2 neutralizing mAB from the same company (InvivoGen). Pre-in-
cubation of all mABs was performed for 1 hour before adding recombinant CagY fragments, GST or rFliC as control as described in




To produce immune-complexes of TLR5, 13 107 of HEK293 TLR5+ cells (mock control or infectedwithHp) were harvestedwith a cell
scraper and washed with ice-cold PBS to remove unbound bacteria. The cells were then lysed in lysis buffer (20 mmol/L Tris-HCl pH
7.2, 5 mmol/L EDTA, 150 mmol/L NaCl, 10% glycerol, 1 mmol/L Na3VO4, COMPLETE and 1% Triton X-100) for 30 min at 4
C (Pa-
chathundikandi et al., 2019). Briefly, all lysates were pre-cleared for 2 h at 4C using protein G–Sepharose according to a protocol by
the manufacturer (GE Healthcare). Rabbit polyclonal a-TLR5 antibodies (2 mg) were added to each supernatant followed by incuba-
tion for 12 h rotation at 4C. Protein G-Sepharose was added for 2 h to form immune complexes, that were precipitated and washed
with lysis buffer (1x) and PBS (3x). Subsequently, all precipitates were subjected to western blot analysis, which is described below.
Western blot analyses
Infected AGS, HEK293 and control cells were collected with a cell scraper, and boiled for 5 min in 1x SDS-PAGE buffer, followed by
SDS-PAGE on 6%–10% polyacrylamide gels. Separated proteins in the gels were then blotted using PVDFmembranes (Immobilon-
P, Merck Millipore, Darmstadt/Germany). The membranes were then blocked for 1 h at room temperature with TBS-T buffer (25 mM
Tris-HCl pH 7.4, 140 mM NaCl, 0.1% Tween-20) containing either 5% skim milk or 3% BSA, followed by incubation with antibodies.
Polyclonal a-TLR5 and monoclonal a-GAPDH antibodies were purchased from Santa Cruz Biotechnology (USA). Phosphorylated
and non-phosphorylated CagA protein species were detected by subsequent incubation of the blots with the mouse monoclonal
a-pan-phosphotyrosine antibody PY99 (Santa Cruz Biotechnology, USA) and a rabbit polyclonal a-CagA antibody (Austral Biolog-
icals, San Ramon/USA). The a-Flagellin (Roure et al., 2012) and a-CagL (Kwok et al., 2007) antibodies were described previously. The
rabbit polyclonal a-CagE, and a-CagX antibodies were produced by immunizing two rabbits with protein-specific peptides coupled
to the carrier protein LPH (Limulus polyphemus haemocyanin) as described (Hirsch et al., 2012; Tegtmeyer et al., 2013). In addition,
we produced a mouse antibody against the CagY epitope between amino acid 1263 to 1569 (based on strain 26695), which was
amplified by PCR, cloned in the pET28a expression vector and the 6xHis-tagged protein was purified as described above for the
CagY MRRs. Immunizations were performed according to the German ‘‘Tierschutzgesetz and Tierschutz-Versuchsverordnung’’ in
completion of an EU directive (2010/63/EU). The corresponding protocol was recorded and commended through the LALLF M-V
(Landesamt f€ur Landwirtschaft, Lebensmittelsicherheit & Fischerei Mecklenburg-Vorpommern) in Rostock/Germany. Each antibody
was affinity-purified using a standard protocol (Biogenes GmbH, Berlin/Germany). Antibody detection was performed with the
following secondary antibodies: horseradish peroxidase-conjugated a-rabbit or a-mouse polyvalent goat immunoglobulins (Thermo
Fisher Scientific, Massachusetts/USA). Blots were developed using the ECL Prime chemiluminescence Western Blot system by GE
Healthcare (Krause- Gruszczynska et al., 2007; Boehm et al., 2011).
CagY peptide SPOT arrays
Due to the large size of CagY (strain PMSS1, NCBI Protein accession number: AQM72202), we produced two peptide array mem-
branes per protein with 425 and 220 peptides, respectively, using the SPOT-synthesis technique (Beutling et al., 2008). This method
detects binding sites corresponding to linear amino acid sequences, and is not suited to detect binding sites that are dependent on
protein folding. Membrane-1 contains amino acid residues 1-1,287 and membrane-2 the amino acids 1,288-1950. In brief, the pep-
tides were directly synthesized on amino-functionalized cellulose membranes using Fmoc/tert-butyl chemistry. Every spot contains
5 nmol of the peptide. To identify in vitro binding partners, the peptide arrays were blocked with 10 mL blocking buffer containing
23 blocking buffer concentrate (Sigma-Aldrich) with 5% (w/v) sucrose in TBS-T (0.02M sodium phosphate pH 7, 0.1M sodium chlo-
ride and 0.05% Tween-20). After overnight incubation at room temperature, five mg/mL zebrafish rTLR5 (His-tagged) protein were
added in blocking buffer, followed by incubation for 4 h at 20C on a rotating device. Subsequently, the peptide arrays were washed
four times using 15 mL TBS-T buffer, followed by adding 40 mL mouse a-Tetra-His-antibody or a-TLR5 antibody in 8 mL blocking
buffer. Antibody incubation was for 2 h at 20C (QIAGEN), and bound antibody detection was performed using secondary horse-
radish peroxidase conjugated a-mouse antibodies (Life Technology, Darmstadt, Germany) in 10 mL blocking buffer. The ECL Prime
chemiluminescence kit was used for developing as outlined above. As expected, themock control spots on the blots without peptide
revealed no signal.
Protein binding assay
Purified recombinant CagY fragments, FliC and GST control protein (1 mg each) were immobilized on PVDF membranes as Dotblots
using the BioDot SF apparatus (BioRad, Munich/Germany), followed by incubation with 1 mg recombinant rTLR5 using the protocol
described above for the peptide SPOT arrays. Bound rTLR5 was visualized using a-TLR5 antibodies according to the same protocol
and signal intensities were quantified densitometrically (Tegtmeyer et al., 2011).
CagY sequence analysis
The CagY protein sequence from the Hp strain PMSS1 (NCBI Protein accession number: OWT35138) was used as a query in Blastp
(Altschul et al., 1990) against theHp taxon (Taxid: 210) in GenBank. The obtained CagY protein sequences and the TLR binding pep-
tides shown in Figure 4A were aligned in Muscle (Edgar, 2004). Then, the most parsimonious blocks were extracted from the align-
ment using Gblocks (Castresana, 2000). The phylogenetic tree was built applying the Monte Carlo Markov Chain (MCMC) method
using MrBayes v3.2 (Ronquist et al., 2012). The analysis was performed for 100,000 generations, sampling every 100 generationsCell Reports 32, 108159, September 15, 2020 e8
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using the COILS program (Lupas et al., 1991; https://embnet.vital-it.ch/software/COILS_form.html) with standard settings. Second-
ary structure prediction was donewith PsiPred (Buchan et al., 2013) and SLiMFinder (Davey et al., 2010) was used formotif detection.
Histology
Gastric biopsies from patients of the following groups were applied: non-infected controls (n = 10), lymphocytic gastritis (n = 10),
MALT lymphoma (n = 9), autoimmune gastritis (n = 10), intestinal type of gastric cancer (n = 10) and diffuse type of gastric cancer
(n = 7). Sections were fixed with 4% neutral buffered formalin followed by paraffinization in an increasing series of alcohol and xylene,
respectively. The biopsies were oriented manually for perpendicular cutting of the paraffin blocks. Four micron thick slides were
generated and stained with hematoxylin and eosin. In addition, Warthin-Starry Sliver staining was used for detection of H. pylori.
All studies on human biopsies have been reviewed and approved by the Ethics Commission Office of FAUErlangen/Germany (license
number 344_16 BC).
Immunohistochemistry
To visualize specifically TLR5 in cytoplasmatic epithelial and inflammatory cells, we used monoclonal mouse a-TLR5 antibodies
(Zytomed). For this purpose, deparaffinised biopsy sections from 56 patients were heated in citrate buffer (pH 6.0) for 20 min using
a microwave. Endogenous peroxidase was blocked by 20 min incubation using 0.3% hydrogen peroxidase in methanol. Afterward,
the sections were rinsed in washing buffer, followed by blocking of non-specific binding using normal serum purchased from Nichirei
(Tokyo/Japan). For primary a-TLR5 antibody binding, overnight incubation was carried out at 4C. Subsequently, an incubation step
of 30minwith biotinylated secondary antibodywas accomplished. Substrate bindingwas achieved by the streptavidin–biotin–perox-
idasemethod. Furthermore, we performed a counterstaining using haemalaun of all samples. In addition, renal positive controls were
included, and staining against TLR5 was only considered positive whenever the controls revealed appropriate results. When this was
not the case, stainings were repeated until internal controls showed the expected results. TLR5 signals gradually increased with the
grade ofH. pylori colonization and severity of inflammation in the gastric mucosa as classified according to the updated Sydney Sys-
tem (Dixon et al., 1996). The ImmunoReactive Score (IRS) system by Remmele and Stegner (1987) was performed for scoring by
two blinded pathologists. According to this scheme, the percentage of positive cells was divided into five grades: 0–4 (0%,
<10%, 10%–50%, 51%–80%, >80%) multiplied with the grade of immunohistochemical stain intensity (graded from 0 to 3). Pictures
shown in Figures 6A–6F are taken at 40x magnification.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were done at least three times with similar results and were analyzed with GraphPad Prism statistical software
(version 8.0). All TLR5 activation and protein binding data were evaluated via One-way analysis of variance (ANOVA) followed by
Tukey’s test. Statistics for the LigandTracer experiments were done by Two-way-ANOVA. Quantitation of TLR5 immunohistochem-
istry staining were evaluated via Student’s t test. Significant differences were defined by p% 0.05 (*), p% 0.01 (**), p% 0.001 (***) and
p % 0.0001 (****).e9 Cell Reports 32, 108159, September 15, 2020
